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Control of serum phosphate without any phosphate binders in patients
treated with nocturnal hemodialysis. We compared the efficacy and the
long-term effects of nocturnal hemodialysis (NHD) versus conventional
hemodialysis (CHD) in controlling serum phosphate levels in patients with
end-stage renal disease (ESRD). Patients underwent thrice weekly CHD
and were subsequently switched to NHD six nights weekly. In the “acute”
study serum and dialysate phosphate were measured during and after
dialysis, and the total dialysate was collected to calculate mass solute
removal. Although pre-dialysis (1.7 6 0.6 vs. 1.5 6 0.8 mM) serum
phosphate levels were similar in CHD and NHD, respectively, post-
dialysis levels were slightly lower with CHD (0.7 6 0.2 vs. 0.8 6 0.2 mM,
P , 0.05). The measured phosphate removed per session of CHD or NHD
was comparable, 25.3 6 7.5 versus 26.9 6 9.8 mmol/session, respectively.
On the other hand, the cumulative weekly phosphate removal was
significantly higher with NHD as compared to CHD, 75.8 6 22.5 versus
161.6 6 59.0 mmol/week (P , 0.01). In the “chronic” study serum
phosphate levels were measured monthly for five months on CHD and for
five months after the patients were switched to NHD. Dietary phosphate
intake and the dosage of phosphate binders were tabulated. Serum
phosphate levels fell during NHD: 2.1 6 0.5 mM at the beginning of the
study and 1.3 6 0.2 mM five months after being switched to NHD (P ,
0.001). At the same time dietary phosphate intake increased by 50%. By
the fourth month of NHD therapy none of the patients was taking any
phosphate binders. In conclusion, NHD is more effective in controlling
serum phosphate levels than CHD, allowing patients to discontinue their
phosphate binders completely and to ingest a more liberal diet.
Impaired phosphate excretion with resulting hyperphos-
phatemia is one of the earliest consequences of chronic renal
failure. Hyperphosphatemia in turn plays an important role in the
development of secondary hyperparathyroidism [1, 2], which is
associated with significant morbidity. Consequently, prevention
and treatment of hyperphosphatemia is one of the major treat-
ment goals of end-stage renal failure.
There are several ways to deal with this important problem [3].
The first modality of therapy is restriction of dietary phosphate
intake. A usual Western diet contains 800 to 2000 mg/day (26 to
67 mmol/day) of phosphate [4, 5]. The phosphate content of the
different diets prescribed to patients with renal failure varies
between 550 and 1100 mg/day (18 to 36 mmol/day), depending
mainly on the protein content of the diet [6, 7]. Certainly, a low
phosphate diet is difficult to achieve if a protein intake of 1.0 to
1.2 g/kg/day is to be maintained. As the intestinal absorption of
phosphate ranges between 40 to 80% of the ingested amount [8,
9], the amount of absorbed phosphate varies between 10 and 30
mmol/day or 100 to 210 mmol/week.
Reduction of phosphate absorption can be achieved by the use
of phosphate binders. After recognition of the severe toxic effects
caused by chronic administration of aluminum containing medi-
cations [10, 11], the use of the aluminum-based phosphate binders
has declined markedly and currently calcium salts have been used
more extensively [12]. Although calcium salts are effective phos-
phate binders, they are not without side effects, including the
frequent development of hypercalcemia. As well, patient compli-
ance is often difficult to achieve [12].
The last modality of treatment is enhanced removal of phos-
phate by dialysis therapy. The average dialytic phosphate removal
is 20 to 40 mmol/session with hemodialysis [3, 13–15], that is, 60 to
120 mmol/week, and 10 to 12 mmol/day (70 to 85 mmol/week)
with CAPD [3]. This means that many patients on dialysis are in
a net positive phosphate balance, even with optimal dietary
compliance [5, 16].
Since dialysis treatment was first used for the treatment of
uremia, one of its major goals was the control of serum phosphate
levels by enhanced removal of phosphate. It was thought that
altering the buffer in the dialysate may increase the amount of
phosphate removed. Unfortunately, several studies have demon-
strated that this modification of the buffer does not lead to
increased phosphate removal [14, 17]. Hemofiltration, by increas-
ing the ultrafiltration rate and thereby taking advantage of the
convective transfer, seems to be somewhat more effective than
conventional hemodialysis [14, 18], although the amounts re-
moved in those studies were still inadequate in maintaining
normal serum phosphate levels. Zucchelli and Santoro have
shown that the dialyzer surface area and the predialysis serum
phosphate level were the major determinants of dialytic phos-
phate removal [14]. In their study the type of dialyzer used did not
affect the amount of phosphate removed. Similarly, Chauveau et
al found no significant differences in phosphate removal among
five different dialyzers [19].
From kinetic studies we know that during both conventional
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hemodialysis and hemofiltration serum phosphate drops rapidly in
the first one to two hours of the treatment and then it reaches a
plateau [17, 20]. It has also been well documented that serum
phosphate concentration rises relatively quickly in the first few
hours after termination of dialysis (rebound phenomenon) [17,
20]. The amount of phosphate removed decreases significantly in
the second half of the dialysis. Accordingly, it was suggested that
prolonging the duration of dialysis would not achieve enhanced
phosphate removal [18]. In fact, several authors have concluded
that adequate control of serum phosphate would not be achiev-
able by extracorporeal therapy alone [5, 16, 21].
This study aimed to assess the efficacy of nocturnal hemodial-
ysis (NHD) [22], a new dialysis modality developed at the
Wellesley Central Hospital, in removing phosphate from patients
with ESRD and to evaluate the long-term effects of this dialysis
modality on serum phosphate concentrations.
METHODS
Nocturnal hemodialysis
During the period of April 1994 and October 1995, eight
patients were recruited for this study: four males and four
females. They were trained for NHD by a dedicated research
nurse.
Vascular access was achieved via a long-term internal jugular
vein catheter (Uldall Cook catheter) developed by the research
group and manufactured by Cook Critical Care (Bloomington, IN,
USA) [23, 24]. To prevent accidental disconnection, the blood
lines, which were joined to the Luer-lock of the arterial and
venous limbs of the Cook catheter, were taped and enclosed at the
point of connection with a lightweight “locking box” that effec-
tively prevents physical separation of the lines from the catheter
even in the unlikely event that they might become unscrewed.
A Fresenius (series H) dialysis machine was modified to
produce a dialysate flow of 100 ml/min (6 liter/hr). The blood flow
rate was between 250 to 300 ml/min. At these blood and dialysate
flow rates there is nearly 90% equilibration of urea from the
incoming plasma to the outflowing dialysate.
All patients were dialyzed with a small surface area (0.7 m2)
polysulfone dialyzer (Fresenius F40), and with dialysate contain-
ing calcium 1.25 mM, sodium 140 mM, potassium 2 mM and
bicarbonate 30 mM. The patients were dialyzed for eight to ten
hours, six to seven nights per week, while asleep. All of the main
functions displayed on the front panel of the Fresenius machine
were monitored remotely via modem at the NHD research office.
Acute study
We designed the acute study to compare the efficiency of NHD
versus CHD with respect to phosphate removal, and also to
compare the kinetics of the changes in serum phosphate levels
during and immediately after the dialysis sessions.
Paired studies were undertaken in the eight patients. In order to
obtain comparable data, patients enrolled in the study were
switched to a “standardized” dialysis protocol (CHD; conven-
tional hemodialysis) for four weeks: four hours of dialysis with a
Fresenius F 80 dialyzer, blood flow rate of 300 to 350 ml/min and
dialysate flow rate of 500 ml/min. The composition of the dialysate
was as follows: calcium 1.25 mM, sodium 135 mM, potassium 1 to
3 mM, and bicarbonate 35 mM. After these four weeks all of the
patients spent six nights in the research center, performing
nocturnal dialysis (NHD): eight hours of dialysis with a Fresenius
F 40 dialyzer, blood flow of 250 to 300 ml/min and dialysate flow
of 100 ml/min.
Serum phosphate, urea and calcium were measured during
dialysis at times 0, 15, 120 and 225 minutes (CHD) or 0, 15, 240
and 465 minutes (NHD) into the respective treatments, as well as
at 10, 30, 60 and 120 minutes post-dialysis (Fig. 1). At the same
time points the concentration of phosphate and urea in the
outflowing dialysate was also measured. To compare the two
modalities we calculated phosphate clearance using the following
formula [14]:
Dialysate clearance ~KD! 5
Qdo 3 Cdo
Cpi
where Qdo is the flow rate of outflowing dialysate, Cdo is the
phosphate concentration in the outflowing dialysate, and Cpi is the
serum concentration of phosphate in the “arterial” line.
We also collected the total spent dialysate to calculate solute
mass removal. Weekly solute removal was calculated by multiply-
ing the amount of solute removed during one session (second
session for CHD, the fourth for NHD) by the number of sessions
performed per week. These measurements were performed on the
third week of CHD and on the fourth night of NHD.
Chronic study
After the successful completion of the test week, seven patients
continued to dialyze nightly at home. Monthly blood work in-
cluded serum calcium, phosphate and parathormone measure-
ments. These results were compared with each patient’s earlier
monthly laboratory results obtained while they were still on CHD.
Dietary phosphate intake, calcitriol and phosphate binder dosage
were tabulated. Dose of calcium carbonate was recorded when the
monthly blood work was done (first week of each month). Diet
records were obtained for three consecutive days two months
before and six months after starting NHD. Daily phosphate intake
Fig. 1. Relative changes in serum phosphate levels during and after
dialysis. Symbols are: (M) conventional hemodialysis (CHD); (f) noctur-
nal hemodialysis (NHD). Note horizontal axis is not drawn to scale; 0, 1,
2, 3 correspond to times 0, 15, 120 and 225 minutes for CHD and 0, 15, 120
and 465 minutes for NHD into the treatments. p1, p2, p3 and p4 denote
10, 30, 60 and 120 minutes after termination of both dialysis treatments
(rebound phase). Values are mean 6 SD, N 5 8. *P , 0.05, NHD versus
CHD.
Mucsi et al: Phosphate control with nocturnal hemodialysis1400
was calculated using the Food Processor® (ESHA Research)
software. Serum phosphorus was measured using a Vitros 750
analyzer manufactured by Johnson & Johnson Clinical Diagnosis
Inc., using a colorimetric method [25].
Statistical analysis
Statistical analysis was performed using the SPSS software. The
results are presented as means 6 SD or median (range). The
comparisons were done by using the Student’s paired t-test or
Wilcoxon Matched Pairs rank test.
RESULTS
Table 1 shows that in the acute study, pre-dialysis (1.7 6 0.6 vs.
1.5 6 0.8 mM) and post-dialysis (0.7 6 0.2 vs. 0.8 6 0.2 mM, P ,
0.05) serum phosphate levels were fairly similar with CHD as
compared to NHD, respectively, as were pre-dialysis and post-
dialysis serum calcium levels (pre-dialysis 2.32 6 0.13 vs. 2.29 6
0.12 mmol/liter; post-dialysis 2.09 6 0.13 vs. 2.19 6 0.09 mmol/
liter for CHD vs. NHD, respectively; P 5 NS in both cases). As
well, serum urea levels were similar with the two modalities.
Figure 1 is a plot of the relative changes in serum phosphate
levels after the end of dialysis for both CHD and NHD. During
CHD, serum phosphate declined to 50 6 14% of the pre-dialysis
value at 10 minutes after the end of dialysis, and rose by 38% to
68 6 20% of the pre-dialysis value by the end of two hours (P ,
0.05).
During NHD, serum phosphate declined to 65% 6 21% of the
pre-dialysis value and rose by 16% to 73 6 18% at the end of two
hours (P 5 0.03). At the end of the two hour period post-dialysis,
the serum phosphate levels were comparable with CHD versus
NHD (1.0 6 0.3 vs. 0.9 6 0.2, P 5 NS).
The calculated phosphate clearance for NHD was less than half
of the clearance obtained with CHD (147.5 6 31.3 vs. 65.5 6 7.8
ml/min for CHD vs. NHD, respectively; P , 0.001). This is not
surprising because the surface area of the dialyzer used for NHD
is much smaller than the one used for CHD. Furthermore, the
dialysate flow rate during NHD is only one fifth of the rate during
CHD. The calculated urea clearances showed qualitatively similar
results (228.4 6 11.1 vs. 83.4 6 5.3 ml/min for CHD vs. NHD,
respectively; P , 0.001). Despite the lower clearance the overall
removal of phosphate during one session (measured from the
total spent dialysate) was similar with CHD versus NHD, related
to the longer dialysis time with NHD: 25.3 6 7.5 versus 26.9 6 9.8
mmol/session, respectively (P 5 NS; Fig. 2). Consequently, the
total weekly phosphate removal with NHD was almost twice the
amount removed by CHD (161.6 6 59.0 vs. 75.8 6 22.5 mmol/
week, P , 0.01). At the same time, there was no significant
difference in the weekly urea removal between the two methods
(Fig. 2).
During the long-term follow-up in the chronic phase of the
study the mean serum phosphate concentration of our patients
decreased significantly after they were switched to NHD. The
level was 2.1 6 0.5 mM prior to starting NHD and 1.3 6 0.2 mM
by five months after starting NHD (P , 0.001; Fig. 3). By the third
month on NHD all of our patients had near normal serum
phosphate levels (serum phosphate , 1.6 mM) and remained thus
during the following two months of our observation. This oc-
curred at a time when we were able to reduce the dose of calcium
carbonate in all patients from a median of 2.4 (1.4 to 4.5) g/day at
the beginning of the study period to 0 (0 to 1.5) g/day by the third
month on NHD (P , 0.05). By the fifth month of NHD therapy
none of the patients was taking any phosphate binders. During the
same period dietary phosphate intake had increased by 50%, from
24.8 6 8.1 to 37.1 6 8.6 mmol/day (P , 0.01; Fig. 3). Serum
albumin, magnesium and bicarbonate did not change significantly
during the follow-up period (Table 2).
Although calcium fluxes were not measured, the serum calcium
concentrations of our patients remained stable during both the
acute and chronic studies, and remained within or close to the
normal range (2.2 to 2.5 mM). The serum iPTH concentrations
showed great variability over the study period. All but a single
Fig. 2. Solute removal with conventional hemodialysis (CHD; M) versus
nocturnal hemodialysis (NHD; f). (A) Solute removal during one dialysis
session as measured in total spent dialysate collected in aliquots. Phos-
phate and urea concentrations were measured in each aliquot and the
total solute removed was calculated. (B) Weekly solute removal. Solute
removal during one session was multiplied by the number of treatments
per week. Values are mean 6 SD, N 5 8. *P , 0.01 for the difference
between the CHD versus NHD. (Note: To convert mM to mg/dl, use the
following conversion factors: for PO4 multiply by 3.096 and for urea by
2.8.)
Table 1. Pre-dialysis and post-dialysis serum values in the acute study
CHD NHD P value
Phosphate
Pre-dialysis mM 1.7 6 0.6 1.5 6 0.8 NS
Post-dialysis mM 0.7 6 0.2 0.8 6 0.2 ,0.05
Calcium
Pre-dialysis mM 2.3 6 0.1 2.3 6 0.1 NS
Post-dialysis mM 2.1 6 0.13 2.2 6 0.1 NS
Urea
Pre-dialysis mM 16.8 6 3.4 14.2 6 3.5 NS
Post-dialysis mM 4.9 6 1.8 5.0 6 1.3 NS
Data are: mean 6 SD; N 5 8. Note: To convert mM to mg/dl, use the
following conversion factors: for PO4 multiply by 3.096; for Ca multiply by
4 and for urea by 2.8. Abbreviations are: CHD, conventional hemodialysis;
NHD, nocturnal hemodialysis.
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diabetic patient were placed on oral calcitriol treatment for
elevated serum iPTH levels. There was a decreasing trend in the
median serum iPTH concentration as the dose of calcitriol
treatment was adjusted, but the difference was not statistically
significant (Table 2). During the NHD period the median iPTH
concentration stayed elevated in the range of three to five times
the upper limit of the normal range, which are levels associated
with normal bone turnover in dialysis patients [26].
DISCUSSION
Hyperphosphatemia is a major factor in the pathogenesis of
secondary hyperparathyroidism in patients with end-stage renal
failure, resulting in significant morbidity. In general, there are
three ways to control serum phosphate levels in patients with
ESRD. Reduction of dietary phosphate intake is impossible
without making significant restrictions to the usual Western diet,
and this is not easily achieved in the long term. The goal of
decreasing dietary phosphate intake is also in conflict with the
need to maintain adequate protein intake in these hypercatabolic
patients. The second therapeutic tool in controlling the serum
phosphate level is the use of phosphate binders. As mentioned
earlier, despite their efficiency in decreasing intestinal absorption
of phosphate, the use of calcium salts (which are the main
phosphate binders used) is not without problems [3].
Consequently, there has been great interest in finding methods
for enhancing the removal of phosphate during dialysis. Several
studies have been done to assess these factors and to find ways to
increase this parameter [14, 15, 17, 18, 27]. The conclusion of
these studies was that the main determinants of dialytic phosphate
removal are the pre-dialysis serum phosphate level and the
surface area of the dialyzer. Several other factors were found to
affect the net removal of phosphate during dialysis, but these
factors had only minor effects. On the other hand, most of the
studies found that neither the type of membrane [14], nor the
buffer used in the dialysate [14, 17], nor the type of renal
replacement therapy (that is, hemodialysis, hemofiltration or even
hemodiafiltration) [14, 18] had major effects on the mass transfer
of phosphate from the patient to the dialysate.
In different studies the net phosphate removal during a dialysis
session varied between 15 and 40 mmol, depending in part on the
pre-dialysis serum phosphate level [13, 15, 28]. In most of the
studies in which the dialytic phosphate removal was around or
above 30 mmol/session, the pre-dialysis phosphate concentration
was around 2 mmol/liter, which is unacceptable by today’s stan-
dards. Analyzing the results from previous papers and from their
own study, Hou et al argued that the currently used dialysis
methods cannot remove the phosphate absorbed from a restricted
diet even if the serum phosphate was allowed to remain at levels
of 2.1 mM [15]. Based on these results several authors concluded
that the existing methods for renal replacement therapy are not
efficient enough in controlling the serum phosphate level of
patients with end-stage renal failure without the use of phosphate
binders [5, 15, 16, 21].
Here we report our findings with eight patients who have been
dialyzing themselves at home, eight to ten hours per night, six
nights a week. This novel form of dialysis therapy is described in
greater detail elsewhere. To date sepsis rates have not increased
[22]. On the other hand, determining the portion of ESRD
patients who might benefit from this therapy remains to be
evaluated. Interestingly, our data differ from those obtained from
patients undergoing daily hemodialysis. These patients continue
to require phosphate binders, which may possibly be related to an
increased dietary intake of phosphate (U. Buoncristiani, personal
communication).
By comparing the mass transfer of solutes, and phosphate in
particular, during a solitary session of CHD and NHD, we found
that net phosphate removal was almost identical with the two
methods, despite the greater clearance with CHD. This is related
to the longer duration of the treatment. The overall kinetics of
Fig. 3. Serum phosphate, dose of calcium carbonate and dietary phos-
phate intake during conventional hemodialysis (CHD; M) versus noctur-
nal hemodialysis (NHD; f). (A) Serum phosphate levels as measured
monthly. (B) Daily oral dose of calcium carbonate as phosphate binder.
Values are median and range as data distribution not normal. (C) Dietary
phosphate intake. Values are mean 6 SD, N 5 7. *P , 0.05; **P , 0.01
as compared to month 25. (Note: To convert mM to mg/dl for PO4
multiply values by 3.096.)
Table 2. Serum values while on conventional hemodialysis (CHD) and
after 6 months on nocturnal hemodialysis (NHD)
CHD NHD P value
Phosphate mM 2.1 6 0.5 1.3 6 0.2 ,0.001
Calcium mM 2.4 6 0.2 2.4 6 0.5 NS
Urea mM 18.7 6 2.1 11.4 6 1.0 ,0.01
Creatinine mM 893 6 41 545 6 21 ,0.01
iPTH pM 49.7 6 26.7 19.0 6 23.9 NS
Albumin g/liter 42.0 6 0.7 42.1 6 1.0 NS
Bicarbonate mM 23.0 6 2.6 24.4 6 1.8 NS
Magnesium mM 0.94 6 0.04 0.97 6 0.16 NS
Data are mean 6 SD; N 5 7. Note: To convert mM to mg/dl, use the
following conversion factors: for phosphate multiply by 3.096, for calcium
multiply by 4, for urea by 2.8 and for magnesium by 2.43. To convert mM
to mg/dl for serum creatinine multiply values by 0.011. To obtain serum
iPTH level in pg/ml multiply by 10. To convert serum albumin to g/dl,
divide by 10.
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serum phosphate levels during and immediately after dialysis were
also similar. However, quantitative differences exist between the
two modalities. With both modalities, serum phosphate declined
during the dialysis treatment. However, during the rebound phase
with NHD, the rise in serum phosphate barely reached statistical
significance during the two hour period after stopping dialysis.
This suggests a greater opportunity for equilibration of phosphate
with extravascular stores.
We had assumed that with more prolonged dialysis we would be
able to remove substantially more phosphate with NHD than with
CHD. Certainly the longer duration of treatment with NHD did
not cause greater changes in serum values than those usually seen
with CHD, due to the slower rate of solute removal with NHD.
Similar to the findings with conventional hemodialysis [17, 18, 20],
we saw a rapid decrease in the serum phosphate concentration
during NHD: it dropped significantly during the first half of the
session, but during the second half the relative changes in the
serum phosphate became smaller and smaller.
As has been documented in several reports [15, 17, 27], net
phosphate removal during one dialysis session in our study
correlated closely with the pre-dialysis serum phosphate levels. At
a mean predialysis serum phosphate of 1.7 mM the daily phos-
phate removal was 27 mmol. This would allow our patients to
consume an average Western diet containing 40 to 50 mmol of
phosphate per day and still remain in phosphate balance (assum-
ing that about 50% of the dietary phosphate would be absorbed).
Even if the predialysis serum phosphate should decrease some-
what further during NHD (as was the case in our chronic study),
the daily phosphate removal would still be able to match a fairly
liberal dietary phosphate intake.
The efficiency of NHD in controlling serum phosphate over the
long term was demonstrated in the chronic study. We showed that
within five months all patients switched to NHD therapy became
almost normophosphatemic. In fact, they were able to maintain
close to normal serum phosphate levels while increasing their
phosphate intake significantly as well as discontinuing all their
phosphate binders. During the study period the mean phosphate
intake rose from 25 to almost 40 mmol/day and the serum
phosphate levels stabilized at near normal levels. The greater
removal of phosphate with NHD, balanced by a greater intake of
phosphate and discontinuation of enteric phosphate binding
resulted in a new steady state. The other factor resulting in this
new balance was the lower predialysis serum phosphate level,
which ultimately also dictated the final steady state level.
Due to the relatively short follow up and the small number of
patients we cannot draw conclusions about the effect of NHD on
the function of the parathyroid gland. However, it has been shown
that hyperphosphatemia plays an important role in both the
emergence and maintenance of secondary hyperparathyroidism
[2] It has also been documented that hyperphosphatemia is an
important factor in the failure of calcitriol therapy to control
secondary hyperparathyroidism [2]. Consequently NHD, by main-
taining normophosphatemia, could lay the ground for successful
control of parathyroid function, with the use of calcitriol if
necessary, and may be of additional benefit in preventing uremic
osteodystrophy.
The spectrum of uremic bone disease has changed dramatically
in the last ten years [29]. Probably the most striking change has
been the large increase in the prevalence of adynamic bone
disease without significant aluminum staining. The pathogenesis
of this entity is not completely understood yet, but it is believed
that one factor may be “oversuppression” of the parathyroid gland
by the use of calcitriol and/or calcium salt phosphate binders [30,
31]. Nocturnal hemodialysis also might be beneficial in this
respect. Discontinuing calcium-containing phosphate binders
would prevent the hypercalcemic episodes that are thought to be
involved in oversuppression of the parathyroid gland. Further-
more, as discussed above, we might be able to achieve a smoother
iPTH profile in normophosphatemic patients. Therefore, NHD
might also be helpful in preventing the development of adynamic
bone disease.
Clearly, further studies are needed to obtain additional data on
the complex effect of NHD on bone and mineral metabolism.
Serum phosphate is only one factor in this complex picture and
further follow up and careful analysis of the data will be necessary
to establish the optimal treatment conditions. For example, the
dialysate calcium concentration might need to be increased to
compensate for the potential decrease in intestinal calcium ab-
sorption after stopping calcium carbonate. Also, the exact place of
calcitriol supplementation will need to be determined. Further-
more, the target serum iPTH concentration which maintains a
normal bone turnover in these patients, who are supposedly less
uremic than an average dialysis patient, has to be determined.
In conclusion, we believe that our findings are very promising.
This is the first documentation of control of serum phosphate by
dialysis alone. Nocturnal hemodialysis has proven to be safe,
extremely well tolerated, and by this method we were able to
achieve remarkable blood purification [22]. This resulted in a
more liberal diet with fewer medication needs.
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